Results 91 to 100 of about 36,176 (202)

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study

Journal of Thrombosis and Haemostasis, 2019
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti‐von Willebrand Factor Nanobody®, is effective for treating aTTP episodes and is well tolerated.
P. Knoebl, S. Cataland, F. Peyvandi, P. Coppo, M. Scully, J. K. Kremer Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, Jessica Minkue Mi Edou, H. de Winter, F. Callewaert   +11 more
semanticscholar   +1 more source

Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura.

New England Journal of Medicine, 2019
Managing Acquired TTP without Plasma Exchange A case of acquired thrombotic thrombocytopenic purpura is reported in a Jehovah’s Witness who had neurologic manifestations but would not accept plasma...
Deepak P. Chander, M. Loch, S. Cataland, J. George   +3 more
semanticscholar   +1 more source

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

Expert Review of Clinical Pharmacology, 2019
Introduction: Caplacizumab is a humanized anti-von Willebrand Factor (vWF) Nanobody® for the treatment of acquired Thrombotic Thrombocytopenic Purpura (aTTP). Caplacizumab targets the A1-domain of vWF, inhibiting the interaction between vWF and platelets.
M. Sargentini‐Maier, Philip De Decker, C. Tersteeg, J. Canvin, F. Callewaert, H. de Winter   +5 more
semanticscholar   +1 more source

Effect of blood groups on acquired and congenital thrombotic thrombocytopenic purpura and clinical correlation: Multi-center Turkish cohort study

Hematology, Transfusion and Cell Therapy
Background: Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic hemolytic anemia associated with ADAMTS-13 deficiency, a cleaving protease of von Willebrand factor (vWF).
Cevat İlteriş Kıkılı, Damla Ortaboz, Melek Yanaşık, Muhlis Cem Ar, Sevgi Kalayoğlu Beşışık   +4 more
doaj   +1 more source

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.

Blood Advances, 2017
Our objective was to describe new observations from the Oklahoma Thrombotic Thrombocytopenic Purpura (TTP) Registry experience (November 1995 through December 2015) on the diagnosis of TTP along with patients' clinical features and their outcomes.
E. E. Page, J. K. Kremer Hovinga, Deirdra R. Terrell, S. Vesely, J. George   +4 more
semanticscholar   +1 more source

Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura

Haematologica, 2014
Anti-ADAMTS13 autoantibodies are the main cause of acquired thrombotic thrombocytopenic purpura. Binding of these antibodies to ADAMTS13 eventually results in the formation of antigen-antibody immune complexes.
Silvia Ferrari, Kristina Palavra, Bernadette Gruber, Johanna A. Kremer Hovinga, Paul Knöbl, Claudine Caron, Caroline Cromwell, Louis Aledort, Barbara Plaimauer, Peter L. Turecek, Hanspeter Rottensteiner, Friedrich Scheiflinger   +11 more
doaj   +1 more source

Pulmonary Tuberculosis Complicated by Thrombotic Thrombocytopenic Purpura: A Case Report and Literature Review

Infection and Drug Resistance
Jun Zheng,1 Xiaohong Pan,2 Yiyun Jiang3 1Department of Rehabilitation, Nanxing Health Service Center, Shangcheng, Hangzhou, Zhejiang, 310000, People’s Republic of China; 2Tuberculosis Care Unit, Hospital of Integrated Traditional Chinese and Western ...
Zheng J, Pan X, Jiang Y
doaj  

The ADAMTS131239–1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope

Haematologica, 2017
Acquired thrombotic thrombocytopenic purpura is a rare and severe disease characterized by auto-antibodies directed against “A Disintegrin And Metalloproteinase with Thrombospondin type 1 repeats, 13th member" (ADAMTS13), a plasma protein involved in ...
Laurent Gilardin, Sandrine Delignat, Ivan Peyron, Mathieu Ing, Yu-Chun Lone, Bagirath Gangadharan, Baptiste Michard, Yousra Kherabi, Meenu Sharma, Anastas Pashov, Jean-Baptiste Latouche, Mohamad Hamieh, Olivier Toutirais, Pascale Loiseau, Lionel Galicier, Agnès Veyradier, Srini Kaveri, Bernard Maillère, Paul Coppo, Sébastien Lacroix-Desmazes   +19 more
doaj   +1 more source

Vitamin B12 Deficiency and Hemoglobin H Disease Early Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Series of Unfortunate Events

Case Reports in Hematology, 2015
We herein would like to report an interesting case of a patient who presented with anemia and thrombocytopenia combined with high serum Lactic Dehydrogenase where Thrombotic Thrombocytopenic Purpura was originally considered.
Panagiotis Andreadis, Stamatia Theodoridou, Marily Pasakiotou, Stergios Arapoglou, Eleni Gigi, Evaggelia Vetsiou, Efthymia Vlachaki   +6 more
doaj   +1 more source

Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura

Haematologica, 2012
Background Severe ADAMTS13 deficiency is a critical component of the pathogenesis of idiopathic thrombotic thrombocytopenic purpura but is found only in about 60% of patients clinically diagnosed with this disease.Design and Methods Over a period of 8 ...
Rahel Froehlich-Zahnd, James N. George, Sara K. Vesely, Deirdra R. Terrell, Khatira Aboulfatova, Jing-Fei Dong, Brenda M. Luken, Jan Voorberg, Ulrich Budde, Irmela Sulzer, Bernhard Lämmle, Johanna A. Kremer Hovinga   +11 more
doaj   +1 more source